Clotting time in INTEM (A) corresponds to activated partial thrombin time. Clotting time in INTEM was not prolonged in any patient. Clotting time in EXTEM (B) corresponds to prothrombin time. A strongly prolonged clotting time in EXTEM was found in one patient of every group, except HC with all other measured parameters being unchanged. No differences between groups were detected. Lines indicate mean ± standard error of the mean for each group. Dotted lines indicate normal range. HC healthy control, CKD5 patients with chronic kidney disease stage G5, HD patients on hemodialysis, PD patients on peritoneal dialysis.</p
<p>Clotting times are provided in seconds; AU denotes arbitrary unit; NA denotes not available.</p
Data are given as medians with interquartile ranges. *p HC healthy control, CKD5 patients with chron...
Hypofibrinolysis is a risk factor for venous and arterial thrombosis, and can be assessed by using a...
Data are given as medians with interquartile ranges. ***p HC healthy control, CKD5 patients with chr...
Background: To determine mean prothrombin time and activated partial thromboplastin time in patients...
FIBTEM reflects the plasmatic part of clot firmness. Clot firmness tended to be increased in patient...
Objective: To explore how cytochalasin D (CyD) affects clot initiation and to compare clotting times...
As a rule, clotting times obtained in prothrombin-time estimations become longer the more a plasma i...
As a rule, clotting times obtained in prothrombin-time estimations become longer the more a plasma i...
<p>For TEM, the parameters clotting time (CT: A), clot formation time (CFT: B) and maximum clot firm...
<p>(A) Clotting times of plasma samples incubated with buffer, 5G9, 10H10 or IgG. (B) Clotting times...
An increased bleeding risk is reported for patients with end-stage renal disease. This study aims to...
The platelet function analyzer (PFA) test measured platelet aggregate formation under high shear rat...
The clinical usefulness of a chromogenic method for prothrombin time (PT) determination has been ass...
Background: Rotational thromboelastometry (ROTEM (R)) relies on citrated blood samples, which are re...
<p>Clotting times are provided in seconds; AU denotes arbitrary unit; NA denotes not available.</p
Data are given as medians with interquartile ranges. *p HC healthy control, CKD5 patients with chron...
Hypofibrinolysis is a risk factor for venous and arterial thrombosis, and can be assessed by using a...
Data are given as medians with interquartile ranges. ***p HC healthy control, CKD5 patients with chr...
Background: To determine mean prothrombin time and activated partial thromboplastin time in patients...
FIBTEM reflects the plasmatic part of clot firmness. Clot firmness tended to be increased in patient...
Objective: To explore how cytochalasin D (CyD) affects clot initiation and to compare clotting times...
As a rule, clotting times obtained in prothrombin-time estimations become longer the more a plasma i...
As a rule, clotting times obtained in prothrombin-time estimations become longer the more a plasma i...
<p>For TEM, the parameters clotting time (CT: A), clot formation time (CFT: B) and maximum clot firm...
<p>(A) Clotting times of plasma samples incubated with buffer, 5G9, 10H10 or IgG. (B) Clotting times...
An increased bleeding risk is reported for patients with end-stage renal disease. This study aims to...
The platelet function analyzer (PFA) test measured platelet aggregate formation under high shear rat...
The clinical usefulness of a chromogenic method for prothrombin time (PT) determination has been ass...
Background: Rotational thromboelastometry (ROTEM (R)) relies on citrated blood samples, which are re...
<p>Clotting times are provided in seconds; AU denotes arbitrary unit; NA denotes not available.</p
Data are given as medians with interquartile ranges. *p HC healthy control, CKD5 patients with chron...
Hypofibrinolysis is a risk factor for venous and arterial thrombosis, and can be assessed by using a...